Spatial Diagnostic Test
IVD-grade spatial biomarker test for clinical treatment selection in head-and-neck squamous cell carcinoma (HNSCC) and beyond.
Patient-Specific Risk Stratification
Each patient receives an individualized risk profile based on the spatial biology of their tumor microenvironment, enabling clinicians to move beyond population-level staging toward truly personalized treatment decisions.
Composite Spatial Biomarker
Our first-in-class composite biomarker integrates multiple spatial features of the tumor and its microenvironment - cell phenotypes, tissue architecture, and neighborhood interactions - into a single prognostic score that outperforms conventional markers.
Patent PendingActionable Prognostic Report
A clear, clinician-friendly report is delivered directly to the treating physician, providing an actionable risk classification to guide therapy selection - reducing uncertainty and improving patient outcomes.
Clinical Validation Partners
We are partnering with leading international clinical centers to validate our diagnostic test in multi-site studies, ensuring the highest standards of clinical evidence before market entry.
Target Indications
Head & Neck Cancer (HNSCC)
Our lead diagnostic targets head-and-neck squamous cell carcinoma, where current staging fails to identify patients who would benefit from treatment de-escalation or intensification.
Expansion to Additional Solid Cancers
The platform architecture is designed to extend to other solid tumor types where spatial biology provides predictive value beyond current standard of care.
Regulatory Pathway
Our diagnostic product follows a staged regulatory strategy toward IVDR Class C certification in the European Union.
Research Use Only - platform validated in 650-patient study
In-house clinical use under Article 5.5 exemption
Full IVDR Class C certification for broad clinical deployment
Interested in our diagnostic pipeline?
Get in touch to learn about partnership and co-development opportunities.
▶ Get in touch with us